Recent Finacing
Recent Raise
Cortendo is a biopharmaceutical company developing levoketoconazole (COR-003) in the Phase 3 SONICS trial for endogenous Cushing’s syndrome, focused on orphan endocrine disorders and cortisol inhibition.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors